Methylenetetrahydrofolate reductase C677T mutation and nonalcoholic fatty liver disease

Digestive Diseases and Sciences

Volumn 52, Issue 5, 2007, Pages 1183-1186

  Serin, Ender ^a   Güçlü, Mustafa ^a   Ataç, F Belgin ^a   Verdi, Hasibe ^a   Kayaselçuk, Fazilet ^a   Özer, Birol ^a   Bilezikçi, Banu ^a   Yilmaz, Uǧur ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Methylenetetrahydrofolate reductase (MTHFR) gene mutation; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ADULT; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; LIVER HISTOLOGY; MALE; MUTATIONAL ANALYSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; STEATOSIS;

ADULT; CASE-CONTROL STUDIES; CYTOSINE; DISEASE PROGRESSION; FATTY LIVER; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THYMINE; TURKEY;

EID: 34247266690     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9565-7     Document Type: Article

References (21)

1. Day CP (2002) Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 16:663-78
2. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N (2001) Non-alcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 50:1844-1850
3. Hayden MR, Tyagi SC (2004) Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation. Nutr J 10:1-23
4. Setola E, Monti LD, Galluccio E, Palloshi A, Fragasso G, Paroni R, Magni F, Sandoli EP, Lucotti P, Costa S, Fermo I, Galli-Kienle M, Origgi A, Margonato A, Piatti P (2004) Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia. Eur J Endocrinol 151:483-489
5. Mansoor MA, Bergmark C, Svardal AM, Lonning PE, Ueland PM (1995) Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Homocysteine and peripheral vascular disease. Arterioscler Thromb Vasc Biol 15:232-240
6. Heinecke JS (1988) Superoxide mediated oxidation of low density lipoproteins by thiols. In: Cerutti PA, Cerutti JM, McCord I, Fridovich I (eds) Oxy-radicals inmolecular biology and pathology. Alan R. Liss, 3186, pp 433-447
7. Ueland PM, Hustad S, Schneede J, Refsum H, Volsett SE (2001) Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22:195-201
8. Kang SS, Wong PWK, Bock HG, Horwitz A, Grix A (1991) Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrafolate reductase mutation. Am J Hum Genet 38:546-551
9. Akar N, Akar E, Akçay R, Avcu F, Yalci̧n A, Cin S (2000) Effect of methylenetetrafolate reductase 677 C-T, 1298 A-C, and 1317 T-C on factor V 1691 mutation in Turkish deep vein thrombosis patients. Thromb Res 9:163-167
10. Yilmaz H, Agachan B, Ergen A, Karaalib ZE, Isbir T (2004) Methylenetetrafolate reductase C677T mutation and left ventricular hypertrophy in Turkish patients with type II diabetes mellitus. J Biochem Mol Biol 37:234-238
11. Kleiner DE, Brunt EM, Van Nata M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ, for the Nonalcoholic Steatohepatitis Clinical Research Network (2005). Hepatology 41:1313-1321
12. Miller SA, Dykes DD, Polesky HS (1998) Simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 20:1433-1408
13. Ozbek N, Atac FB, Yildirim SV, Verdi H, Yazici C, Yilmaz BT, Tokel NK (2005) Analysis of prothrombotic mutations and polymorphisms in children who developed thrombosis in the perioperative period of congenital cardiac surgery. Cardiol Young 15:19-25
14. Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, Banner BF (1999) Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 31:421-429
15. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Tailoli E, Fiorelli G, Fargion S (2002) Tumor necrosis factor α promotor polymorphism and insulin resistance in nonalcoholic liver disease. Gastroenterology 122:274-280
16. Namikawa C, Shu-Ping Z, Vyselaar JR, Nozaki Y, Nemoto Y, Ono M, Akisawa N, Saibara T, Hiroi M, Enzan H, Onishi S (2004) Polymorphisms of microsomal triglyceride transfer protein gene andmanganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 40:781-786
17. Ferretti G, Bacchetti T, 5136 C, Vignini A, Nanetti L, Curatola G (2004) Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J Cell Biochem 92:351-360
18. Heydrick SJ, Weiss N, Thomas SR, Cap AP, Pimentel DR, Loscalzo J, Keaney Jr JF (2004) L-Homocysteine and L-homocystine stereospecifically induce endothelial nitric oxide synthase-dependent lipid peroxidation in endothelial cells. Free Radic Biol Med 36:632-640
19. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, 5300 I (1991) Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324:1149-1155
20. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR (1996) Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759-762
21. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. (2001) Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120:1183-1192